In a study of Ixekizumab for moderate-to-severe psoriasis with 1346 participants (NCT01646177), 17.4% of patients developed treatment-related anti-drug antibodies (TE-ADAs) over 60 weeks, and nine patients developed high-titer TE-ADAs, demonstrating a poor clinical response (Reich et al., 2018). This evidence concerns the gene AGPS and psoriasis.